Korea’s Green Cross To Seek Regulatory Approval For Biobetter Of Shire’s Elaprase In Japan, China
This article was originally published in PharmAsia News
Executive Summary
Because of the limited number of Hunter syndrome patients worldwide, Green Cross is looking to expand sales of its biosimilar Hunterase from South Korea to Japan and China – BIO Korea 2012.